Patents by Inventor David Boothman
David Boothman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170182030Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: March 9, 2017Publication date: June 29, 2017Applicants: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. HERGENROTHER, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Patent number: 9631041Abstract: Disclosed herein are compounds comprising a polymer conjugated with a pH-sensitive prodrug of beta-lapachone, wherein the compound is capable of forming a micelle, and wherein the pH-sensitive prodrug comprises a pH-sensitive linker selected from the group consisting of: an aryl imine and an aliphatic imine. Also provided are micelles comprised of such polymer-prodrug conjugates. Further provided are methods for treating cancer with the micelles.Type: GrantFiled: August 11, 2011Date of Patent: April 25, 2017Assignee: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, David Boothman, Yinjian Zhou, Erik Bey
-
Patent number: 9611266Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: January 11, 2016Date of Patent: April 4, 2017Assignees: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Patent number: 9469878Abstract: Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.Type: GrantFiled: September 22, 2011Date of Patent: October 18, 2016Assignee: The Board of Regents of the University of Texas SystemInventors: David Boothman, Jinming Gao, Erik Bey, Ying Dong
-
Publication number: 20160220706Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: ApplicationFiled: March 17, 2016Publication date: August 4, 2016Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Jinming Gao, David BOOTHMAN, Kejin ZHOU, Xiaonan HUANG, Yiguang WANG
-
Publication number: 20160122348Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: January 11, 2016Publication date: May 5, 2016Applicants: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20160030457Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.Type: ApplicationFiled: April 8, 2014Publication date: February 4, 2016Applicants: The Board of Regents of the University of Texas System, The Board of Trustees of University of IllinoisInventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Lifen CAO, Jinming GAO, Xiumei HUANG, Xiuquan LUO, Xinpeng MA, Zachary R. MOORE, Elizabeth I. PARKINSON
-
Patent number: 9233960Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: GrantFiled: October 12, 2012Date of Patent: January 12, 2016Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20150011509Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.Type: ApplicationFiled: October 12, 2012Publication date: January 8, 2015Applicants: The Board of Trustees of the University of Illnois, The Board of Regents of the University of Texas SystemInventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
-
Publication number: 20140023590Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: ApplicationFiled: August 11, 2011Publication date: January 23, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, David Boothman, Kejin Zhou, Xiaonan Huang, Yiguang Wang
-
Publication number: 20130331426Abstract: Disclosed herein are compounds comprising a polymer conjugated with a pH-sensitive prodrug of beta-lapachone, wherein the compound is capable of forming a micelle, and wherein the pH-sensitive prodrug comprises a pH-sensitive linker selected from the group consisting of: an aryl imine and an aliphatic imine. Also provided are micelles comprised of such polymer-prodrug conjugates. Further provided are methods for treating cancer with the micelles.Type: ApplicationFiled: August 11, 2011Publication date: December 12, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Jinming GAO, David Boothman, Yinjian Zhou, Erik Bey
-
Publication number: 20130253046Abstract: Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.Type: ApplicationFiled: September 22, 2011Publication date: September 26, 2013Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor: David BOOTHMAN
-
Publication number: 20050175668Abstract: In part, the present invention is directed to a system comprising a lapachone or a prodrug thereof and a polymer, such as a biocompatible and optionally biodegradable polymer, methods for treatment using the subject polymer compositions, and methods of making and using the same. In another part, the present invention includes inclusion complexes of a lapachone or a prodrug thereof and a cyclodextrin, preferably a ?-cyclodextrin, such as hydroxypropyl ?-cyclodextrin, e.g., to improve the solubility of the lapachone or prodrug thereof.Type: ApplicationFiled: March 4, 2005Publication date: August 11, 2005Applicant: Case Western Reserve UniversityInventors: David Boothman, Jinming Gao, Norased Nasongkla, John Pink
-
Patent number: 6890950Abstract: In part, the present invention is directed to a system comprising a lapachone or a prodrug thereof and a polymer, such as a biocompatible and optionally biodegradable polymer, methods for treatment using the subject polymer compositions, and methods of making and using the same. In another part, the present invention includes inclusion complexes of a lapachone or a prodrug thereof and a cyclodextrin, preferably a ?-cyclodextrin, such as hydroxypropyl ?-cyclodextrin, e.g., to improve the solubility of the lapachone or prodrug thereof.Type: GrantFiled: April 23, 2003Date of Patent: May 10, 2005Assignee: Case Western Reserve UniversityInventors: David Boothman, Jinming Gao, Norased Nasongkla, John Pink
-
Publication number: 20040001871Abstract: In part, the present invention is directed to a system comprising a lapachone or a prodrug thereof and a polymer, such as a biocompatible and optionally biodegradable polymer, methods for treatment using the subject polymer compositions, and methods of making and using the same. In another part, the present invention includes inclusion complexes of a lapachone or a prodrug thereof and a cyclodextrin, preferably a &bgr;-cyclodextrin, such as hydroxypropyl &bgr;-cyclodextrin, e.g., to improve the solubility of the lapachone or prodrug thereof.Type: ApplicationFiled: April 23, 2003Publication date: January 1, 2004Inventors: David Boothman, Jinming Gao, Norased Nasongkla, John Pink
-
Patent number: 5763625Abstract: 3-Substituted-.beta.-lapachone analogs and their use either alone or to augment chemotherapy or radiotherapy to induce programmed neoplastic cell death without exhibiting toxicity to surrounding normal cells are disclosed. In particular, 3-allyl-.beta.-lapachones, 3-alkyl-.beta.-lapachones and 3-halo-.beta.-lapachones were found to be Topoisomerase (Topo I) inhibitors. When these analogs are used alone there is a reversible single-strand break in the DNA of neoplastic cells causing apoptosis and cell death in some cells. However, when these analogs are combined with chemotherapy or X-irradiation, an irreversible Topo I-mediated break is achieved. A new and more efficient chemical synthesis of the compounds is also disclosed.Type: GrantFiled: April 25, 1995Date of Patent: June 9, 1998Assignee: Wisconsin Alumni Research FoundationInventors: David A. Boothman, Benjamin J. Frydman, Donald T. Witiak